Eli Lilly

Eli Lilly to launch its obesity drug at competitive price in India in 2025

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

Eli Lilly to boost weight-loss drug supply with $3 billion expansion

The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world

Novo Nordisk India execs urge early Wegovy launch as rival Eli Lilly looms

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

Novo Nordisk aware of deaths linked to compounded weight-loss drug copies

This was a result of significant investments to expand its manufacturing capacity and "ongoing communication" with the FDA, the company said at the time

Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast

The Denmark-based company said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth

Eli Lilly's blockbuster weight-loss drug no longer in shortage in US: USFDA

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been resolved

Novo Nordisk pares 2024 profit outlook amid competition from Eli Lilly

The Danish company lowered its forecast for operating profit growth this year to between 20% and 28% in local currencies, compared to its previous forecast of 22% to 30%

Eli Lilly's popular drug Mounjaro stuck at Indian regulators' counter

Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance

Explained: Eli Lilly's 'miracle' weight-loss drug soon to enter India

The American pharmaceutical giant is set to introduce its obesity drug, a competitor to Nova Nordisk's Ozempic, in India as early as next year

Eli Lilly expects to launch obesity drug in India next year, says CEO

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions

Eli Lilly closer to joining Magnificent Seven in $1 trn market cap club

"Could Lilly be the first $1 trillion biopharma stock?" Morgan Stanley's Terence Flynn and colleagues asked in a note to clients. "We continue to see a path for further upside"

USFDA finds new manufacturing lapses at pharma co Eli Lilly's plant: Report

Lilly said in a statement to Reuters that the inspection followed a company request to the FDA to make a change to its manufacture of migraine treatment Emgality

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Suven starts Phase 3 trial for first home-grown Alzheimer's drug

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

What is Twitter's blue tick?

Twitter's move to sell its blue check badge for $8 made aerospace company Lockheed Martin and pharma giant Eli Lilly & Co fall prey to impersonators. What is blue check? How did it come into being?

Twitter's big headache: Brand impostors thanks to the $8 verification

Users started creating accounts pretending to be major brands and politicians, fooling users and potentially jeopardizing Twitter's now-shaky reputation with top advertisers

Experimental obesity drug may be alternative to bariatric surgery

The drug maker claimed that the new drug Tirzepatide has enabled people with obesity or who are overweight to lose about 22.5 per cent of their body weight

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

Bajaj Healthcare seeks compulsory licence for Covid-19 drug Baricitinib

Eli Lilly has granted voluntary license to 6 Indian drugmakers for Baricitinib

Eli Lilly to seek FDA approval for potential Alzheimer's drug

Shares of Eli Lilly and Co. jumped more than 8%, or $18.59, to $235.69 at the opening bell Thursday.